BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

42 related articles for article (PubMed ID: 9704729)

  • 21. Antitumor activity of bent metallocenes: electronic structure analysis using DFT computations.
    Senthilnathan D; Vaideeswaran S; Venuvanalingam P; Frenking G
    J Mol Model; 2011 Mar; 17(3):465-75. PubMed ID: 20495841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis, Structure and Biological Activity of Amide-Functionalized Titanocenyls: Improving their Cytotoxic Properties.
    Gao LM; Matta J; Rheingold AL; Meléndez E
    J Organomet Chem; 2009 Dec; 694(26):4134-4139. PubMed ID: 20177431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spectroscopic and Thermal Characterization of the Host-Guest Interactions between α-, β-, and γ-cyclodextrins and vanadocene dichloride.
    Morales A; Weber RT; Melendez E
    Appl Organomet Chem; 2008 Jun; 22(8):440-450. PubMed ID: 19881887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Titanium(IV) complexes: cytotoxicity and cellular uptake of titanium(IV) complexes on caco-2 cell line.
    Hernández R; Méndez J; Lamboy J; Torres M; Román FR; Meléndez E
    Toxicol In Vitro; 2010 Feb; 24(1):178-83. PubMed ID: 19772913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Water-soluble molybdenocene complexes with both proliferative and antiproliferative effects on cancer cell lines and their binding interactions with human serum albumin.
    Feliciano I; Matta J; Meléndez E
    J Biol Inorg Chem; 2009 Sep; 14(7):1109-17. PubMed ID: 19536567
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A proposed mechanism for the inhibitory effect of the anticancer agent titanocene dichloride on tumour gelatinases and other proteolytic enzymes.
    Pavlaki M; Debeli K; Triantaphyllidou IE; Klouras N; Giannopoulou E; Aletras AJ
    J Biol Inorg Chem; 2009 Aug; 14(6):947-57. PubMed ID: 19390879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intracellular mapping of the distribution of metals derived from the antitumor metallocenes.
    Waern JB; Harris HH; Lai B; Cai Z; Harding MM; Dillon CT
    J Biol Inorg Chem; 2005 Aug; 10(5):443-52. PubMed ID: 15906108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A hypothesis concerning the relationship of cellular pharmakokinetics to optimal scheduling of anti-cancer agents.
    Weiss AJ; Manthei R
    Oncology; 1988; 45(6):448-52. PubMed ID: 3054673
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors.
    Korfel A; Scheulen ME; Schmoll HJ; Gründel O; Harstrick A; Knoche M; Fels LM; Skorzec M; Bach F; Baumgart J; Sass G; Seeber S; Thiel E; Berdel WE
    Clin Cancer Res; 1998 Nov; 4(11):2701-8. PubMed ID: 9829732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.
    Berg SL; Blaney SM; Adamson PC; O'Brien M; Poplack DG; Arndt C; Blatt J; Balis FM
    J Clin Oncol; 1998 Jan; 16(1):181-6. PubMed ID: 9440741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer.
    Toussaint C; Izzo J; Spielmann M; Merle S; May-Levin F; Armand JP; Lacombe D; Tursz T; Sunderland M; Chabot GG
    J Clin Oncol; 1994 Oct; 12(10):2102-12. PubMed ID: 7931480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation.
    Rinaldi DA; Burris HA; Dorr FA; Woodworth JR; Kuhn JG; Eckardt JR; Rodriguez G; Corso SW; Fields SM; Langley C
    J Clin Oncol; 1995 Nov; 13(11):2842-50. PubMed ID: 7595747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer.
    Christodoulou CV; Ferry DR; Fyfe DW; Young A; Doran J; Sheehan TM; Eliopoulos A; Hale K; Baumgart J; Sass G; Kerr DJ
    J Clin Oncol; 1998 Aug; 16(8):2761-9. PubMed ID: 9704729
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.